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In this issue of the Journal (1), we are presented with 1-year
outcomes of a fourth-generation drug-eluting stent (DES):
an everolimus-eluting bioresorbable vascular scaffold (E-
BVS). Made of thick strut poly-L-lactide, with another
lactide acting as a controlled release polymer coating, the
stent elutes everolimus to prevent smooth muscle cell
proliferation: the new and improved (less recoil compared
with a prior version) E-BVS releases everolimus over 30
days, and the stent degrades into lactic acid over a 2-year
period (2–4). To understand the potential for enhanced late
loss and recoil with a bioresorbable scaffold, the authors
investigated the 12-month outcomes of a 56-patient registry
of low-risk patients receiving the E-BVS. The authors
demonstrate, despite the potential for recoil or variable drug
delivery (5), an E-BVS late loss of 0.3 mm with a
corresponding 3.5% restenosis rate. These results are con-
firmed by intravascular ultrasound and optical coherence
tomography (OCT) substudies demonstrating that 95%
of stent struts are covered at 12-month follow-up.
See page 1578
Developing the DES family tree. Development of more
biocompatible polymers as well as thinner stent struts and
polymer coatings (6) is improving efficacy and safety of
second-generation DES compared with the early taxol-eluting
stents (7). Given the link between certain polymers and
chronic inflammatory responses to DES, it is a natural next
step to develop either a third-generation bioresorbable
polymer/durable platform or a fourth-generation of biore-
sorbable polymer/bioresorbable platform (3,8,9).
The first version of the E-BVS (late loss of 0.44 mm) made
the fourth-generation platform at higher risk of restenosis (10)
as was seen with a magnesium alloy bioresorbable stent
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Medtronic.platform (5). The stronger E-BVS 1.1 (Abbott Vascular, Santa
Clara, California) now being studied allays the risk consider-
ably: late loss of 0.27 mm is consistent with current metallic
scaffold second-generation DES (11). Although one might
initially conclude that there is evidence of ongoing recoil of the
E-BVS by comparing the previously reported 6-month late
loss of 0.19 mm with current 12-month results, this would be
an overstatement: the 6- and 12-month cohorts are entirely
different groups of patients, and comparisons can only state
that there is a general consistency of hyperplasia suppression
seen throughout the first year.
The positive findings of minimal intimal hyperplasia, lack
of late incomplete scaffold apposition, and return of vaso-
motion in some patients should not be overstated from this
relatively small low-risk registry. Caution is found in an
early ischemic failure for a patient with a myocardial
bridge—could there be other situations where coronary
motion stress or architectural demands (ostial lesions, over-
lapping stents, bifurcation stenting) might crack or compro-
mise E-BVS stents? Furthermore, the BVS 1.1 (Abbott
Vascular) is a thick strut stent (150 m), and the patients
presented in this report (median lesion length 10.0 mm)
would not challenge issues of deliverability generally coex-
isting with thick stents. Before declaring BVS 1.1 (Abbott
Vascular) the workhorse stent of our future, the daily
challenges of more complex coronary anatomy will need to
be investigated.
In addition to the potential for anatomic challenges,
clinical scenarios might impact the healing properties of
E-BVS. In an analysis of 51 patients from the CVPath
registry, stable patients (similar to those studied in the
E-BVS registry) were compared with patients with myocar-
dial infarction: DES placement in the setting of myocardial
infarction was associated with a 5-fold increase in uncovered
struts and a 2-fold increase in fibrin deposition and inflam-
mation (12). The interaction between higher-risk plaque
morphology with the drug-eluting nonpermanent scaffold/
polymer requires much more investigation. The authors
plan for a noninferiority trial to compare this novel disap-
pearing DES with current second-generation DES. The
design of this trial is critical to the future of fourth-
generation DES adoption and development.
Of magic and soft endpoints. Assuming that the fourth-
generation DES can meet the delivery and healing chal-
lenges of higher-risk patients, how will we define the clinical
advantages of this exciting new technology? A 50% reduc-
tion in clinical events with a p  0.05 is feasible with a
1,000-patient trial comparing DES with bare-metal stents.
Event rates 6% with the taxol-eluting stents allowed
favorable superiority comparisons with the second-
generation everolimus-eluting stents (7). But, the bar has
been set much higher as we move toward proving the
superiority of E-BVS over current comparators (Fig. 1). We
have 12-month target vessel event rates with second-
generation DES that are 5% in the context of recent
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likely allow fourth-generation DES to become a clinical
reality (showing similar restenosis, target vessel revascular-
ization, and stent thrombosis rates), how will the trial data
be used to inform choice of ever less-expensive second-
generation DES versus more costly third- or fourth-
generation DES in actual practice?
A clinical trial of E-BVS compared with second-
generation DES could require over 20,000 patients to
answer the question of relative superiority of disappearing
stents with respect to late stent thrombosis (13). Given the
realities of clinical trials, such an investigation is unlikely; we
need to live with the ascending event uncertainty that comes
with our successful development pyramid (Fig. 1). Although
the approval process might continue to focus exclusively on
hard events, one can imagine soft competitive advantages
for E-BVS: what if a fourth-generation E-BVS allows
earlier discontinuation of dual antiplatelet therapy (DAPT)
and thus prevents late bleeding complications among high-
risk groups (potentially justifying higher up-front costs for a
fourth-generation DES) (14)? One can see 2 scenarios for
conducting an E-BVS trial with DAPT duration as a soft
but real variable: 1) mandate 24 months of DAPT for the
second-generation DES (as is common in current U.S.
practice) versus 12 months of DAPT for fourth-generation
E-BVS with a 2-year primary endpoint to include both
bleeding and ischemic events; or 2) use the guideline-
recommended 12 months of DAPT for the second-
generation DES and compare with a 6-month duration of
DAPT for the E-BVS and thus return us to an era where 12
Figure 1 The Development Pyramid for 4 Generations of DES
As the stent generations progress, the rate of adverse events decreases. This
leads to increasing superiority uncertainty for each new generation of stent.
Novel soft endpoints might be needed to compare efficacy of newer-generation
drug-eluting stents (DES).months of DAPT was an option but not a requirement.The results demonstrated in this current E-BVS registry
might give pause to the appealing notion that disappearing
stents will not require a full 12 months of DAPT. Magic
would be a DES that removes the clinical correlates of late
stent thrombosis seen with the earlier generation of DES—
uncovered stent struts beyond 6 months, localized inflam-
mation, and endothelial dysfunction (12,15,16). Although
the lactide stent integrity might be lost by 12 months, the
response to acetylcholine injection at the prior stent site is
variable—of 19 patients studied, 10 showed vasoconstric-
tion, 8 showed vasodilatation, and 1 showed no response. In
its worst light, this is consistent with only 42% of patients
demonstrating a healthy endothelial response at 1-year
follow-up. In its best light, we can imagine a substudy of the
planned Phase 3 trial where second-generation DES show
enhanced levels of endothelial dysfunction compared with
fourth-generation bioresorbable scaffolds and thus provide a
rationale for choosing the E-BVS in patients unlikely to
complete 12 months of DAPT. Because the second-
generation DES comparator will not show any vasoconstric-
tion at the scaffold site (due to the permanent metallic
implant), the investigators might wish to compare the
downstream impact on vasoconstriction. This comparison
has been one soft method for demonstrating differences
between second- and first-generation DES (16).
Optical coherence tomography and virtual histology in-
travascular ultrasound offer us 2 other magical methods to
demonstrate superiority of E-BVS. Examination of plaque
components associated with adverse 3-year outcomes by
virtual histology (17) or extent of strut coverage by OCT
might demonstrate differential behavior that is statistically
significant between the E-BVS and the second-generation
DES. A shotgun approach to the magical endpoints in the
pivotal trial is not warranted or safe: as noted by the authors
of this registry with respect to 1 patient: “the diagnostic
procedure was unduly prolonged by IVUS and OCT exam-
inations,” leading to coronary thrombosis. The investigators
will need to choose among the many softer possibilities
(variable DAPT duration, OCT healing, stable plaque by
virtual histology, or more rapid return of normal endothelial
function) for demonstrating the magic of disappearing
stents. Although none of these approaches will prove that
the fourth-generation drug-eluting bioresorbable scaffolds
can remove the risk of late stent thrombosis from the clinical
arena, good magic might be better than absolute uncertainty
in guiding future clinical choices.
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